China Biologic Products, Inc., a biopharmaceutical company, through its subsidiaries, engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human albumin and human immunoglobulin for intravenous injection (IVIG) products for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides injection that is used for the treatment of various original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and a range of cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; human tetanus immunoglobulin for the prevention and therapy of tetanus; and placenta polypeptide that is used for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia caused by various reasons, as well as assists in postoperative heating. The company's products under development comprise human prothrombin complex concentrate; human hepatitis B immunoglobulin (PH4) for intravenous injection; human fibrinogen; Varicella hyperimmune globulins; and Human IVIG. It distributes its products directly or through distributors. The company is based in Beijing, the People's Republic of China.